Phase I Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of CMAB007 and Xolair in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male Subjects
Latest Information Update: 13 Jun 2023
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Pharmacokinetics
- Sponsors Taizhou Mabtech Pharmaceuticals
Most Recent Events
- 13 Jun 2023 New trial record